Study of the Vascular Effects of Serelaxin

Status:
Completed

Trial end date:
2016-08-17

Target enrollment:

Participant gender:

This was a mechanistic study in patients with coronary artery disease on the effects of Serelaxin on micro- and macrovascular function.

Phase 2

Novartis Pharmaceuticals